Genvoya, New Single-Tablet HIV Regimen Containing Tenofovir Alafenamide, Approved By FDA

November 5, 2015

On Nov. 5, the U.S. Food and Drug Administration (FDA) approved elvitegravir/cobicistat/ emtricitabine/tenofovir alafenamide (E/C/F/TAF), which will be marketed as Genvoya, for the treatment of HIV in adults and children over 12.

E/C/F/TAF is a single-tablet combination regimen, the first FDA-approved regimen to contain tenofovir alafenamide (TAF), a prodrug of tenofovir that has been shown to be more potent at lower doses and gentler on the bones and kidneys than tenofovir disoproxil fumarate (TDF, Viread).

Previous clinical trials showed that E/C/F/TAF was noninferior to elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate (Stribild), while offering better bone and kidney safety.

Another clinical trial showed that switching to E/C/F/TAF from efavirenz/tenofovir/emtricitabine (Atripla) maintained viral suppression in addition to bone and kidney safety benefits.

E/C/F/TAF is approved for treatment-naive patients, as well as adults with undetectable viral loads on other regimens, according to the FDA press release. Additionally, E/C/F/TAF is not recommended for patients with severe kidney disease, but can be taken by those with moderate kidney disease.

"Today's approval of a fixed-dose combination containing a new form of tenofovir provides another effective, once-daily complete regimen for patients with HIV-1 infection," said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research, in the press release.

The FDA will decide on two other coformulations containing TAF in early 2016: an updated version of tenofovir/emtricitabine (Truvada) at two different doses for combination with other antiretrovirals, and an updated version of rilpivirine/tenofovir/emtricitabine (Complera).

Warren Tong is the senior science editor for and

Follow Warren on Twitter: @WarrenAtTheBody.

Copyright © 2015 Remedy Health Media, LLC. All rights reserved.

Related Stories

Single-Tablet HIV Regimen Containing Tenofovir Alafenamide Improves Bone and Kidney Safety
This Week in HIV Research: Tenofovir Alafenamide (TAF) Single-Tablet Regimen; Retention in Care; and Better Resistance Test

This article was provided by TheBodyPRO.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.